RYVU THERAPEUTICS ZY-,40/ PLSELVT00013 /
| 2024-10-11 7:31:38 PM | Chg. +0.120 | Volume | Bid8:01:11 PM | Ask8:01:11 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 11.640EUR | +1.04% | 0 Turnover: 0.000 |
-Bid Size: - | -Ask Size: - | 283.85 mill.EUR | - | - |
GlobeNewswire
2023-12-11
Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Me...
GlobeNewswire
2023-12-07
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023
GlobeNewswire
2023-11-29
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2023-10-23
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Soli...
GlobeNewswire
2023-10-04
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2...
GlobeNewswire
2023-09-13
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
GlobeNewswire
2021-06-25
Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021
